PTGX Protagonist Therapeutics, Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1377121 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY163.7%
TTM net income YoY645.5%
TTM EPS YoY616.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin58.6%
Net margin62.0%
FCF margin19.8%
EBITDA margin58.9%
Returns
ROE39.6%
ROA37.0%
ROIC (approx.)56.5%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets5.4%
Debt / equity0.00x
Current ratio19.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio25.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $274.41M | $213.47M | $56.37M | $7.44M | $4.71M | $5.55M | $28.32M | $170.64M |
| Cost of revenue | $1.10M | — | — | — | — | — | — | — |
| Gross profit | $273.31M | — | — | — | — | — | — | — |
| R&D expense | $41.27M | $42.06M | $46.74M | $46.36M | $40.00M | $37.04M | $35.89M | $34.90M |
| SG&A expense | $13.70M | $12.65M | $13.28M | $11.43M | $11.13M | $10.55M | $11.74M | $8.95M |
| Operating income | $218.33M | $158.77M | -$3.65M | -$50.35M | -$46.42M | -$42.04M | -$19.31M | $126.78M |
| Pretax income | $226.57M | $165.11M | $2.28M | -$43.72M | -$39.34M | -$34.60M | -$11.65M | $133.66M |
| Income tax | $6.56M | $2.27M | -$1.50M | $666,000 | $0 | $172,000 | $0 | $1.99M |
| Net income | $220.01M | $162.85M | $3.78M | -$44.38M | -$39.34M | -$34.77M | -$11.65M | $131.67M |
| EBITDA | $218.74M | $159.16M | -$3.24M | -$49.98M | -$46.06M | -$41.74M | -$19.07M | $126.90M |
| EPS (basic) | 3.32 | 2.47 | 0.06 | — | -0.62 | -0.55 | -0.19 | — |
| EPS (diluted) | 3.07 | 2.29 | 0.05 | — | -0.62 | -0.55 | -0.19 | — |
| Weighted avg. shares (diluted) | 71.73M | 71.01M | 70.49M | — | 63.77M | 63.51M | 62.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $498.30M | $420.08M | $193.71M | $128.39M | $113.71M | $168.54M | $139.65M | $97.47M |
| Short-term investments | $301.77M | $362.50M | $354.07M | $438.97M | $462.40M | $401.92M | $434.71M | $321.66M |
| Current assets | $1.10B | $807.15M | $613.46M | $577.57M | $586.42M | $602.53M | $605.86M | $591.64M |
| PP&E, net | $3.32M | $3.46M | $3.78M | $3.86M | $4.10M | $4.11M | $3.53M | $3.19M |
| Total assets | $1.15B | $885.54M | $697.46M | $668.19M | $701.69M | $718.01M | $742.13M | $744.73M |
| Current liabilities | $55.46M | $37.18M | $34.55M | $45.44M | $44.94M | $35.51M | $35.11M | $47.40M |
| Total liabilities | $61.64M | $44.00M | $41.99M | $53.48M | $56.25M | $49.99M | $53.08M | $69.43M |
| Shareholders' equity | $1.08B | $841.54M | $655.47M | $614.71M | $645.44M | $668.02M | $689.05M | $675.29M |
| Shares outstanding | 65.22M | 64.67M | 64.23M | 62.58M | 62.45M | 62.11M | 61.93M | 61.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$23.22M | $219.05M | -$48.94M | -$36.98M | -$1.94M | -$28.78M | $125.36M | -$29.18M |
| Capital expenditure | $237,000 | $168,000 | $215,000 | $144,000 | $88,000 | $813,000 | $545,000 | $310,000 |
| Free cash flow | -$23.46M | $218.88M | -$49.16M | -$37.12M | -$2.02M | -$29.59M | $124.82M | -$29.49M |
| Investing cash flow | $93.43M | -$2.43M | $90.89M | $48.81M | -$58.55M | $54.81M | -$94.40M | -$8.72M |
| Financing cash flow | $8.01M | $9.74M | $23.37M | $2.84M | $5.66M | $2.92M | $11.44M | $4.03M |
| Depreciation & amortization | $409,000 | $397,000 | $407,000 | $376,000 | $361,000 | $304,000 | $239,000 | $118,000 |
| Stock-based compensation | $14.36M | $14.04M | $14.52M | $10.70M | $10.56M | $10.91M | $13.80M | $9.09M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.